Sun Pharma Advanced Research Company Limited share price
NSE: SPARC · ISIN INE232I01014
Key numbers
- Market cap
- ₹ 6,784 Cr
- Current price
- ₹ 209.05
- 52-week high / low
- ₹ 289 / 108
- Stock P/E
- 4.3
- Book value
- ₹ 41.3
- Dividend yield
- 0.00%
- ROCE
- 163.0%
- ROE
- 276.9%
- Debt to equity
- 0.42
- Sales growth (3 yrs)
- -45.3%
- Profit growth (3 yrs)
- -
- 1-year return
- 52.4%
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 10 | 8 | 8 | 1,853 | 40 |
| Operating profit | -52 | -66 | -57 | 1,773 | -34 |
| Net profit | -52 | -76 | -80 | 1,761 | -21 |
| EPS (₹) | -1.60 | -2.34 | -2.48 | 54.27 | -0.64 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.